KumbyAI is the AI-powered analyst that synthesizes news, identifies risks, and delivers actionable intelligence for quality and compliance professionals.
A real-time look at the news KumbyAI is analyzing right now.
Fierce Biotech
less than a minute ago
Transplant-focused precision medicine company CareDx is making a move into the oncology space, scooping up Massachusetts-based biotech Naveris in a deal worth up to $260 million.
Fierce Biotech
less than a minute ago
AstraZeneca has paid $25 million to pick up a preclinical EGFR degrader that was at the center of its existing pact with Pinetree Therapeutics.
Fierce Biotech
less than a minute ago
The FDA has halted U.S. enrollment for Newron Pharmaceuticals’ phase 3 schizophrenia trial, following the death of a patient outside of the country.
Fierce Biotech
less than a minute ago
AstraZeneca has announced it will resume a £300 million investment program in the U.K., seven months after freezing the plans in frustration at national government drug pricing negotiations.
Fierce Biotech
less than a minute ago
The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.
Fierce Biotech
less than a minute ago
Teva Pharmaceuticals has struck a deal to buy Emalex Biosciences for $700 million upfront, positioning the drugmaker to advance a Tourette syndrome candidate that is on the cusp of approval.